Skip to content
DataLookout
Menu

NCT05826964

Levels of Circulating Tumor DNA as a Predictive Marker for Early Switch in Treatment for Patients With Metastatic (Stage IV) Breast Cancer

StatusActive, Not Recruiting
PhasePhase 2
Primary completion (estimated)

At risk: Primary completion moved at least 1 year 4 months later.

Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 7 versions: 6 with changes below, 1 re-verified with no change. See every version on ClinicalTrials.gov ↗

  1. Notable Primary completion pushed from Jul 31, 2026 to Nov 30, 2027 Show 4 more changesShow less
    • Eligibility criteria expanded, about 52 words
    • Study completion pushed from Jul 31, 2029 to Nov 30, 2030
    • Interventions: AI+CDK4/6i (Drug), AKT inhibitor (Drug), Chemotherapy (Drug), Oral SERD (Drug), PARPi (Drug), PI3K inhibitor + AI (Drug), PI3K inhibitor +… to AI+CDK4/6i (Drug), AKT inhibitor (Drug), Chemotherapy (Drug), Oral SERD (Drug), PARPi (Drug), PI3K inhibitor + AI (Drug), PI3K inhibitor +…
    • Secondary endpoints: details revised at 7 of 9 entries
  2. Notable Enrollment target: 500 to 24
    • Trial status: Recruiting to Active, Not Recruiting
    • Site details revised
    v6
  3. Notable Eligibility criteria shortened, about 13 words
    • Interventions: AI+CDK4/6i (Drug), Chemotherapy (Drug), Oral SERD (Drug), PI3K inhibitor + AI (Drug), PI3K inhibitor + SERD (Drug), SERD+CDK4/6i (Drug)… to AI+CDK4/6i (Drug), AKT inhibitor (Drug), Chemotherapy (Drug), Oral SERD (Drug), PARPi (Drug), PI3K inhibitor + AI (Drug), PI3K inhibitor +…
    • Secondary endpoints: 6 to 9
    • Study arms: 3 to 4
    v5
  4. Notable Eligibility criteria expanded, about 57 words
    • Interventions: AI+CDK4/6i (Drug), Chemotherapy (Drug), PI3K inhibitor + AI (Drug), PI3K inhibitor + SERD (Drug), SERD+CDK4/6i (Drug), mTOR inhibitor + AI… to AI+CDK4/6i (Drug), Chemotherapy (Drug), Oral SERD (Drug), PI3K inhibitor + AI (Drug), PI3K inhibitor + SERD (Drug), SERD+CDK4/6i (Drug)…
    v3
  5. Notable Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Jul 31, 2023 to Jun 12, 2023
    • Site details revised
    v2
  6. Study First Submitted
  • Notable: the plan changed

Endpoints

Primary

Progression-Free Survival 1 (PFS1) Among Participants in Step 2
Timeframe: Up to 36 months

Secondary (9)

Number of participants in Step 1 with rising ctDNA ratio > 1
Percentage of participants in Step 1 with rising ctDNA ratio > 1
Time from enrollment to rise in ctDNA ratio > 1 for Participants in Step 1
Overall Response Rate (ORR) Among Participants in Step 2
Clinical Benefit Rate (CBR) Among Participants in Step 2
Show 4 moreShow less
Progression-Free Survival 2 (PFS2) Among Participants in Step 3
Progression-Free Survival 3 (PFS3) Among Participants in Step 3
Overall Response Rate (ORR) Among Participants in Step 3
Clinical Benefit Rate (CBR) Among Participants in Step 3

Arms and interventions

Step 2 Arm 1: No Modification of TherapyExperimental

Participants in Step 2 Arm 1 will first undergo ctDNA monitoring in Step 1, providing blood samples for ctDNA testing at the following timepoints until a rise in ctDNA leading to a ratio (ctDNA result at time of assessment/ctDNA level at baseline) greater than (\>) 1 occurs: * Cycle 1 day 1 (C1D1), * Day 30 (D30) post-treatment initiation (±3 days), * Day 60 (D60) post-treatment initiation (±3 days), and then * every 8-9 weeks (±1 week). Participants will have no change in standard of care therapy administered in Step 1.

Step 2 Arm 2: Early Switch in TherapyExperimental

Participants in Step 2 Arm 2 undergo an early switch in standard of care therapy received in Step 1: * From AI+CDK4/6i in Step 1 to one of the following alternate endocrine therapies (ET) or chemotherapy: * SERD+CDK4/6i * mTOR Inhibitor + AI * mTOR Inhibitor+SERD * mTOR inhibitor + Selective estrogen receptor modulator * PI3K inhibitor + SERD * AKT inhibitor + SERD * Oral SERD * PARPi * Clinical Trial * Chemotherapy * From SERD+CDK4/6i in Step 1 to one of the following alternate ET or chemotherapy: * mTOR Inhibitor + AI * mTOR Inhibitor+SERD * mTOR inhibitor + Selective estrogen receptor modulator * PI3K inhibitor + AI * PI3K inhibitor + SERD * Oral SERD * PARPi * Clinical Trial * Chemotherapy Participants will receive this therapy for approximately 14 months.

Step 3: Treatment for Patients in Arm 1Experimental

For participants who were randomized to Step 2 Arm 1 and experience first clinical progression. Participants will receive second-line treatment, having the option to change from their AI+CDK4/6i to SERD+CDK4/6i, or from SERD+CDK4/6i treatment to alternative endocrine therapy or chemotherapy. Therapy options for Step 3 are the same as listed for participants randomized to Step 2 Arm 2 and is administered standard of care. Participants will receive this therapy for approximately 6 months.

Step 3: Treatment for Patients in Arm 2Experimental

For participants who were randomized to Step 2 Arm 2 and experience first clinical progression. Total participation duration is approximately 6 months.

Drugs: AI+CDK4/6i, SERD+CDK4/6i, mTOR inhibitor + AI, mTOR inhibitor + SERD, mTOR inhibitor + Selective estrogen receptor modulator, PI3K inhibitor + SERD, PI3K inhibitor + AI, Chemotherapy, Oral SERD, PARPi, AKT inhibitor

Other: Step 3 Arm 2

Sites

1 site in 1 country

  • University of MiamiMiami, Florida, United States